Analystreport

Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) had its price target raised by analysts at HC Wainwright to $9.00. They now have a "buy" rating on the stock.

Catabasis Pharmaceuticals, Inc.  (CATB) 
Last catabasis pharmaceuticals, inc. earnings: 3/10 08:05 am Check Earnings Report
US:NASDAQ Investor Relations: ir.catabasis.com/investor-overview